title: Treatment of acute hypoxemic nonhypercapnic respiratory insufficiency with continuous positive airway pressure delivered by a face mask: A randomized controlled trial.
abstract: BACKGROUND
  Continuous positive airway pressure (CPAP) is widely used in the belief that it may reduce the need for intubation and mechanical ventilation in patients with acute hypoxemic respiratory insufficiency.
  
  
  OBJECTIVE
  To compare the physiologic effects and the clinical efficacy of CPAP vs standard oxygen therapy in patients with acute hypoxemic, nonhypercapnic respiratory insufficiency.
  
  
  METHODS
  Randomized, concealed, and unblinded trial of 123 consecutive adult patients who were admitted to 6 intensive care units between September 1997 and January 1999 with a PaO(2)/FIO(2) ratio of 300 mm Hg or less due to bilateral pulmonary edema (n = 102 with acute lung injury and n = 21 with cardiac disease).
  
  
  METHODS
  Patients were randomly assigned to receive oxygen therapy alone (n = 61) or oxygen therapy plus CPAP (n = 62).
  
  
  METHODS
  Improvement in PaO(2)/FIO(2) ratio, rate of endotracheal intubation at any time during the study, adverse events, length of hospital stay, mortality, and duration of ventilatory assistance, compared between the CPAP and standard treatment groups.
  
  
  RESULTS
  Among the CPAP vs standard therapy groups, respectively, causes of respiratory failure (pneumonia, 54% and 55%), presence of cardiac disease (33% and 35%), severity at admission, and hypoxemia (median [5th-95th percentile] PaO(2)/FIO(2) ratio, 140 [59-288] mm Hg vs 148 [62-283] mm Hg; P =.43) were similarly distributed. After 1 hour of treatment, subjective responses to treatment (P<.001) and median (5th-95th percentile) PaO(2)/FIO(2) ratios were greater with CPAP (203 [45-431] mm Hg vs 151 [73-482] mm Hg; P =.02). No further difference in respiratory indices was observed between the groups. Treatment with CPAP failed to reduce the endotracheal intubation rate (21 [34%] vs 24 [39%] in the standard therapy group; P =.53), hospital mortality (19 [31%] vs 18 [30%]; P =.89), or median (5th-95th percentile) intensive care unit length of stay (6.5 [1-57] days vs 6.0 [1-36] days; P =.43). A higher number of adverse events occurred with CPAP treatment (18 vs 6; P =.01).
  
  
  CONCLUSIONS
  In this study, despite early physiologic improvement, CPAP neither reduced the need for intubation nor improved outcomes in patients with acute hypoxemic, nonhypercapnic respiratory insufficiency primarily due to acute lung injury. JAMA. 2000;284:2352-2360.
authors.affiliation: Service de Réanimation Médicale, Hôpital Henri Mondor, 94010 Créteil, France.
authors.forename: C
authors.initials: C
authors.lastname: Delclaux
authors.forename: E
authors.initials: E
authors.lastname: L'Her
authors.forename: C
authors.initials: C
authors.lastname: Alberti
authors.forename: J
authors.initials: J
authors.lastname: Mancebo
authors.forename: F
authors.initials: F
authors.lastname: Abroug
authors.forename: G
authors.initials: G
authors.lastname: Conti
authors.forename: C
authors.initials: C
authors.lastname: Guérin
authors.forename: F
authors.initials: F
authors.lastname: Schortgen
authors.forename: Y
authors.initials: Y
authors.lastname: Lefort
authors.forename: M
authors.initials: M
authors.lastname: Antonelli
authors.forename: E
authors.initials: E
authors.lastname: Lepage
authors.forename: F
authors.initials: F
authors.lastname: Lemaire
authors.forename: L
authors.initials: L
authors.lastname: Brochard
mesh_terms: D018806:APACHE; D000208:Acute Disease; D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000150:complications; D005260:Female; D006439:Hemodynamics; D006801:Humans; D000860:Hypoxia / Q000150:complications / Q000628:therapy*; D007362:Intensive Care Units; D007442:Intubation, Intratracheal; D008176:Lung Volume Measurements; D008297:Male; D008397:Masks; D008875:Middle Aged; D010092:Oximetry; D010102:Oxygen Inhalation Therapy; D011175:Positive-Pressure Respiration / Q000009:adverse effects / Q000379:methods; D011446:Prospective Studies; D012128:Respiratory Distress Syndrome / Q000150:complications / Q000628:therapy*; D016896:Treatment Outcome